NEET PG Pathology High-Yield Topics — Complete Guide 2026
Master every high-yield pathology topic for NEET PG 2026: cell injury, inflammation, neoplasia, hematopathology, immunopathology, genetic disorders, and systemic pathology with tumor markers, staining patterns, and diagnostic criteria.
Version 1.0 — Published April 2026
Quick Answer
Pathology contributes 18–24 questions to NEET PG — the highest-weighted preclinical subject after Anatomy. Focus on these 8 high-yield areas:
- Cell injury and adaptation — five types of necrosis (coagulative, liquefactive, caseous, fat, fibrinoid) with classic examples; apoptosis vs necrosis distinguishing features; reversible vs irreversible cell injury
- Inflammation and repair — acute vs chronic inflammation mediators; granulomatous diseases and their causative organisms; wound healing phases; keloid vs hypertrophic scar
- Neoplasia — tumor markers by organ system; grading vs staging principles; paraneoplastic syndromes and their associated tumors; oncogenes and tumor suppressor genes
- Hematopathology — anemia classification by MCV with confirmatory lab findings; ALL vs AML vs CLL vs CML comparison; Hodgkin vs non-Hodgkin lymphoma differentiation; Reed-Sternberg cell variants
- Immunopathology — Types I–IV hypersensitivity with mechanism and prototype disease; autoimmune disease antibody-disease associations; transplant rejection types
- Genetic disorders — chromosomal disorder karyotypes and clinical features; single-gene disorder inheritance patterns; trinucleotide repeat diseases; imprinting disorders
- Systemic pathology highlights — organ-specific high-yield: glomerulonephritis patterns, lung cancer types, liver diseases, cardiac pathology, CNS tumors
- Laboratory investigations and staining patterns — special stains and their targets; IHC markers for tumor identification; electron microscopy findings for glomerulonephritis
This guide covers each area with the histological facts, classification tables, and diagnostic criteria that NBE tests — structured so you can retain them under exam pressure.
Pathology is the foundation of clinical medicine. Every diagnosis in every clinical subject rests on pathological principles — the mechanism of cell death determines the clinical picture, the histological pattern identifies the tumor, and the immunological mechanism predicts the treatment. Unlike subjects where memorization alone can carry you through, Pathology rewards conceptual understanding: a student who grasps why coagulative necrosis preserves architecture will never confuse it with liquefactive necrosis, regardless of how the question is phrased.
That conceptual foundation, paired with systematic table-based revision, is what converts Pathology from a feared subject into a reliable source of marks. Use the Pathology subject hub alongside this guide for daily MCQ practice, and apply spaced repetition to the tables in this article using the method described in our spaced repetition guide.
Cell injury and adaptation: the foundation of all pathology
Cell injury is the alteration of normal cellular structure and function that occurs when a cell is exposed to stress beyond its adaptive capacity — and it is the conceptual anchor for every other topic in pathology. Understanding why cells die and how they die determines the clinical manifestations that Medicine and Surgery questions then test.
Reversible vs irreversible cell injury
Reversible injury (cell can recover if stress is removed): cellular swelling (earliest change), fatty change, blebbing of plasma membrane, clumping of chromatin. Earliest light microscopy change is cellular swelling (hydropic change). Earliest ultrastructural changes include ER dilation, ribosomal detachment, and mitochondrial swelling.
Irreversible injury (cell death is inevitable): loss of plasma membrane integrity, massive calcium influx, mitochondrial permeability transition, nuclear changes (pyknosis → karyorrhexis → karyolysis). The point of no return is severe mitochondrial dysfunction combined with plasma membrane damage.
Types of necrosis — the most tested pathology table
| Type | Mechanism | Gross appearance | Microscopy | Classic examples |
|---|---|---|---|---|
| Coagulative | Ischemia (except brain) | Firm, pale, wedge-shaped | Ghost outlines of cells preserved; no nuclei | MI, renal infarct, splenic infarct |
| Liquefactive | Bacterial infection OR brain ischemia | Liquid, pus-filled cavity | Cell architecture completely dissolved | Brain infarct, lung abscess, bacterial abscesses |
| Caseous | Granulomatous infection | Cheese-like, crumbly white | Amorphous granular debris; no cell outlines; surrounded by granuloma | Tuberculosis (pathognomonic), histoplasmosis |
| Fat | Lipase activation | Chalky white deposits (saponification) | Fat cells with shadowy outlines; calcium soap deposits | Acute pancreatitis, traumatic fat necrosis of breast |
| Fibrinoid | Immune complex deposition in vessel walls | Not visible grossly | Bright pink, homogeneous material in vessel walls | Malignant hypertension, polyarteritis nodosa, SLE vasculitis |
| Gangrenous | Ischemia ± infection (composite) | Dry (no bacteria) or wet (bacteria present) | Coagulative ± liquefactive | Diabetic foot, peripheral vascular disease |
NBE examination pattern: Questions present a clinical scenario — a patient with a cortical brain lesion that is fluid-filled, or a pancreatic mass with chalky deposits — and ask for the type of necrosis. Lock the brain-liquefactive and TB-caseous associations as primary recall items.
Apoptosis vs necrosis — differentiating features
| Feature | Apoptosis | Necrosis |
|---|---|---|
| Stimulus | Programmed (physiological or pathological) | Always pathological |
| Cell size | Shrinks (condensation) | Swells |
| Membrane integrity | Maintained | Lost |
| Inflammation | None | Prominent |
| DNA fragmentation | Internucleosomal (ladder pattern on gel) | Random |
| Morphology | Apoptotic bodies, chromatin condensation | Ghost cells, karyorrhexis |
| Energy requirement | ATP-dependent | Passive |
| Examples | Embryonic development, T-cell deletion, p53-mediated | Infarction, toxins, infections |
Key NBE fact: Councilman bodies in viral hepatitis and Civatte bodies in lichen planus are examples of apoptosis — not necrosis. Apoptosis in the liver produces acidophilic (eosinophilic) bodies.
Cellular adaptations
Hypertrophy (increased cell size, no division): cardiac hypertrophy in hypertension — myocardial cells cannot divide, so they enlarge. Hyperplasia (increased cell number): endometrial hyperplasia in estrogen excess — cells CAN divide. Atrophy (reduced cell size): disuse atrophy, denervation atrophy. Metaplasia (one adult cell type to another): Barrett esophagus (squamous → columnar, intestinal type), bronchial squamous metaplasia in smokers. Dysplasia (disordered growth): pre-neoplastic; reversible if stimulus removed.
Inflammation and repair: mediators, granulomas, and wound healing
Inflammation is the vascular and cellular response of living tissue to injury, infection, or foreign material — and it is the mechanism that links pathology to every clinical manifestation of disease. NBE tests inflammation through mediator identification, granuloma cause recognition, and wound healing sequencing.
Acute vs chronic inflammation
| Feature | Acute inflammation | Chronic inflammation |
|---|---|---|
| Duration | Minutes to days | Weeks to months |
| Main cells | Neutrophils | Macrophages, lymphocytes, plasma cells |
| Vascular changes | Vasodilatation, increased permeability | Angiogenesis, fibrosis |
| Outcome | Resolution, abscess, chronic inflammation, fibrous repair | Fibrosis, tissue destruction |
| Mediators | Histamine, prostaglandins, leukotrienes, complement, bradykinin | TNF-alpha, IL-1, IL-6, IFN-gamma |
| Exudate | Neutrophil-rich | Mononuclear-rich |
Chemical mediators — the most tested:
- Histamine: earliest mediator, from mast cells, causes immediate vasodilatation and increased permeability
- Bradykinin: pain, vasodilatation, increased permeability, bronchospasm
- Prostaglandins (PGE2, PGI2): vasodilation, fever, pain sensitization — blocked by NSAIDs (COX inhibition)
- Leukotrienes (LTC4, LTD4, LTE4): bronchoconstriction, slow-reacting substances of anaphylaxis (SRS-A) — blocked by montelukast
- TNF-alpha and IL-1: fever, acute phase response, neutrophil recruitment, systemic effects
- Complement C3a, C5a: anaphylatoxins (mast cell degranulation); C5a also a potent neutrophil chemoattractant
Granulomatous inflammation — causes by organism and disease
A granuloma is a focal area of chronic granulomatous inflammation characterized by aggregates of activated macrophages (epithelioid cells), often with multinucleated giant cells, lymphocytes, and a variable degree of central necrosis.
| Cause | Type of granuloma | Giant cell type | Necrosis | Distinguishing feature |
|---|---|---|---|---|
| Tuberculosis | Caseous granuloma | Langhans giant cells | Caseous central necrosis | AFB on ZN stain; PCR for M. tuberculosis |
| Sarcoidosis | Non-caseating granuloma | Langhans or foreign body | NO necrosis | Schaumann bodies, asteroid bodies; ACE elevated |
| Leprosy | Granulomatous (tuberculoid) or diffuse (lepromatous) | Virchow cells in lepromatous | None | AFB within macrophages (lepromatous) |
| Crohn disease | Non-caseating granuloma | Foreign body type | None | Transmural; skip lesions |
| Cat scratch disease | Stellate granuloma with central suppuration | Rare | Suppurative | Bartonella henselae; warthin-starry stain |
| Fungal (Histoplasma, Coccidioides) | Caseating or non-caseating | Langhans or foreign body | Variable | Silver stain for fungal elements |
| Foreign body reaction | Foreign body granuloma | Foreign body giant cells | None | Polarizable material within giant cells |
| Berylliosis | Non-caseating granuloma | Langhans | None | Mimics sarcoidosis; occupational history |
NBE trap: Sarcoidosis granulomas are non-caseating — the ABSENCE of necrosis distinguishes them from TB. A question presenting bilateral hilar lymphadenopathy + non-caseating granulomas on biopsy = sarcoidosis.
Wound healing — phases and failure modes
Primary intention (clean incised wound, edges approximated):
- Clot formation (hours) — fibrin plug
- Inflammation/neutrophil phase (24–48 hours)
- Proliferative phase (3–5 days) — granulation tissue, angiogenesis, fibroblast migration, collagen III deposition
- Remodeling (weeks to months) — collagen III replaced by collagen I; tensile strength increases to 80% of normal maximum
Factors delaying wound healing: Infection, foreign body, ischemia, malnutrition (vitamin C deficiency impairs collagen cross-linking), diabetes (impaired neutrophil function + microvascular disease), zinc deficiency (impairs cell proliferation), corticosteroids (suppress inflammation and collagen synthesis).
Keloid vs hypertrophic scar:
| Feature | Keloid | Hypertrophic scar |
|---|---|---|
| Extension | Beyond wound margins | Within wound margins |
| Spontaneous regression | No | Yes, over time |
| Predisposition | Dark-skinned individuals; earlobe, chest, deltoid | Any individual |
| Recurrence after excision | High | Low |
Neoplasia: tumor markers, grading, and paraneoplastic syndromes
Neoplasia is the abnormal proliferation of cells that have escaped normal regulatory controls — and it is the single highest-yield pathology area for NEET PG, contributing 6–8 questions per paper. The testable core is concentrated in tumor markers, grading vs staging principles, paraneoplastic syndromes, and molecular oncology.
Tumor markers — the complete NBE table
| Tumor marker | Associated tumor | Clinical use | Key fact |
|---|---|---|---|
| AFP (Alpha-fetoprotein) | Hepatocellular carcinoma, yolk sac tumor (testis) | Screening in cirrhosis, monitoring treatment response | Normal in adults; physiologically elevated in pregnancy and fetal life |
| PSA (Prostate-specific antigen) | Prostate carcinoma | Screening, monitoring | Elevated in BPH and prostatitis — not cancer-specific |
| CEA (Carcinoembryonic antigen) | Colorectal carcinoma (primary); also GI, lung, breast | Monitoring recurrence after resection | Not useful for screening; re-elevated CEA after resection = recurrence |
| CA-125 | Ovarian carcinoma (serous type) | Monitoring treatment, surveillance | Also elevated in endometriosis, PID, pregnancy |
| CA 19-9 | Pancreatic carcinoma (also cholangiocarcinoma, gastric) | Monitoring; surgical resectability decision | Not useful as screening tool |
| CA 15-3 | Breast carcinoma | Monitoring metastatic disease | Not recommended for screening |
| hCG (Beta-hCG) | Choriocarcinoma, hydatidiform mole, mixed germ cell tumors | Diagnosis, monitoring, detecting residual disease | Elevated in normal pregnancy; dramatically elevated in gestational trophoblastic disease |
| LDH | Lymphoma, testicular tumors, Ewing sarcoma | Staging, prognosis | Non-specific; reflects tumor burden |
| Calcitonin | Medullary thyroid carcinoma (C-cell origin) | Diagnosis, family screening in MEN 2A/2B | Pathognomonic association; elevated CEA also seen in MTC |
| Thyroglobulin | Differentiated thyroid carcinoma (papillary, follicular) | Post-thyroidectomy surveillance | Should be undetectable after total thyroidectomy; rising = recurrence |
| S-100 | Melanoma, schwannoma, S-100+ histiocytoses | IHC marker for neural crest origin | Not secreted into blood; tissue IHC marker |
| Chromogranin A | Neuroendocrine tumors (carcinoid, pheochromocytoma, small cell lung) | Serum marker for NET; IHC marker | Useful for carcinoid syndrome follow-up |
| PLAP (Placental alkaline phosphatase) | Seminoma | IHC marker | Distinguishes seminoma from embryonal carcinoma |
Grading vs staging — principles tested by NBE
Grading is a histological assessment of tumor differentiation (how much the tumor resembles normal tissue). It assesses the PRIMARY tumor.
| Grade | Differentiation | Mitoses | Architecture |
|---|---|---|---|
| Grade I (well-differentiated) | Closely resembles normal tissue | Few | Near-normal gland/structure formation |
| Grade II (moderately differentiated) | Moderate resemblance | Moderate | Partially preserved architecture |
| Grade III (poorly differentiated) | Little resemblance | Many | Architecture largely lost |
| Grade IV (anaplastic/undifferentiated) | No resemblance | Numerous, atypical | No recognizable pattern |
Staging uses TNM: Tumor size/extension (T), Nodal involvement (N), Metastasis (M). Staging determines prognosis more reliably than grading for most tumors. Critical NBE point: For prognosis, staging outweighs grading. A well-differentiated (Grade I) tumor that has metastasized (Stage IV) has worse prognosis than a poorly differentiated (Grade III) localized tumor (Stage I).
Paraneoplastic syndromes — high-yield associations
Paraneoplastic syndromes are clinical effects of malignancy that are not due to direct tumor invasion, obstruction, or metastasis — they are mediated by hormones, peptides, or antibodies produced by the tumor.
| Syndrome | Tumor type | Mediator | Key clinical feature |
|---|---|---|---|
| SIADH (hyponatremia) | Small cell lung carcinoma | Ectopic ADH | Euvolemic hyponatremia; serum osmolality <280, urine osmolality >100 |
| Cushing syndrome (ectopic ACTH) | Small cell lung carcinoma, bronchial carcinoid, pancreatic NET | Ectopic ACTH | Ectopic ACTH: NO suppression even with high-dose dexamethasone (unlike pituitary Cushing disease which IS suppressed by high-dose). Rapid hypokalemic alkalosis, hyperpigmentation, muscle wasting — often WITHOUT classic cushingoid features. |
| Hypercalcemia | Squamous cell carcinoma of lung, breast, RCC, myeloma | PTHrP (PTH-related protein) or osteolytic metastases | Most common metabolic complication of malignancy |
| Lambert-Eaton myasthenic syndrome | Small cell lung carcinoma | Anti-VGCC antibodies | Proximal muscle weakness IMPROVES with repeated movement (opposite to MG) |
| Cerebellar degeneration | Lung, breast, ovarian carcinoma | Anti-Yo, anti-Hu antibodies | Ataxia, dysarthria; cerebellar atrophy on MRI |
| Acanthosis nigricans | Gastric carcinoma (most common), lung, uterine | Insulin-like growth factors | Velvety hyperpigmentation in axillae, neck, groin |
| Dermatomyositis/polymyositis | Lung, ovarian, GI malignancies | Immune-mediated | Heliotrope rash, Gottron papules, proximal myopathy |
| Migratory thrombophlebitis (Trousseau sign) | Pancreatic carcinoma (classic), mucin-secreting adenocarcinomas | Mucin activating clotting cascade | Recurrent, migratory venous thrombosis at unusual sites |
| Polycythemia | Renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma | Ectopic EPO | Elevated hematocrit without hypoxia trigger |
| Hypoglycemia | Insulinoma, retroperitoneal sarcoma, hepatocellular carcinoma | Insulin or IGF-2 | Fasting hypoglycemia; serum C-peptide low in IGF-2 cases |
Most tested NBE association: Small cell lung carcinoma causes SIADH, ectopic Cushing, and Lambert-Eaton — a single tumor type behind three distinct paraneoplastic syndromes.
Hematopathology: anemias, leukemias, and lymphomas
Hematopathology is the study of diseases of the blood, bone marrow, and lymphoid organs — contributing 5–7 questions per NEET PG with anemia classification, leukemia differentiation, and lymphoma histology as the primary targets.
Anemia classification by MCV
| Category | MCV | Causes | Distinguishing lab |
|---|---|---|---|
| Microcytic (<80 fL) | Low | Iron deficiency anemia, beta-thalassemia trait, anemia of chronic disease, sideroblastic anemia | Serum ferritin (low in IDA, normal/high in others); HbA2 >3.5% in beta-thal |
| Normocytic (80–100 fL) | Normal | Acute blood loss, hemolytic anemia, aplastic anemia, anemia of chronic disease, renal failure | Reticulocyte count: high = hemolysis/bleeding; low = bone marrow failure |
| Macrocytic (>100 fL) | High | B12 deficiency, folate deficiency, liver disease, hypothyroidism, MDS, alcoholism, drugs (hydroxyurea, methotrexate) | Hypersegmented neutrophils (megaloblastic); peripheral smear is the key differentiator |
Iron deficiency vs beta-thalassemia trait — classic NBE differentiator:
| Parameter | Iron deficiency anemia | Beta-thalassemia trait |
|---|---|---|
| Serum iron | Low | Normal |
| TIBC | High | Normal |
| Ferritin | Low (most sensitive test) | Normal or elevated |
| HbA2 | Normal or low | Elevated (>3.5%) — diagnostic |
| RDW | High (anisocytosis) | Normal |
| Mentzer index (MCV/RBC count) | >13 | <13 |
| Response to iron | Excellent | None |
Leukemia comparison — ALL, AML, CLL, CML
| Feature | ALL | AML | CLL | CML |
|---|---|---|---|---|
| Peak age | Children 2–5 years | Adults, median 65 | Elderly >60 | Adults 40–60 |
| Cell of origin | Lymphoblast (B-cell > T-cell) | Myeloblast | Mature B-lymphocyte | Pluripotent stem cell (granulocytic predominance) |
| Pathognomonic finding | TdT+; CD10+ (CALLA, B-ALL) | Auer rods (MPO+) | Smudge cells; CD5+, CD23+ | Philadelphia chromosome t(9;22) BCR-ABL |
| Cytochemistry | PAS positive (B-ALL) | Sudan black B+, MPO+ | No specific reaction | LAP score LOW (distinguishes from leukemoid reaction) |
| Genetics | t(12;21) [ETV6-RUNX1] most common in pediatric ALL, best prognosis; Ph+ ALL t(9;22) poor-prognosis subset (~20-25% adults) | t(8;21), inv(16) good prognosis; FLT3-ITD poor | Del(17p), del(11q) poor prognosis; del(13q14) good | t(9;22) BCR-ABL; p210 protein |
| Treatment | Multi-agent chemo + CNS prophylaxis (intrathecal MTX) | Induction: 7+3 (cytarabine + daunorubicin); AML-M3 (APL): ATRA + ATO | Watch-and-wait or ibrutinib/venetoclax | Imatinib (TKI) — dramatically changed natural history |
| Prognosis | >85% cure in children; worse in adults | 30–40% long-term remission | Indolent, median survival 10+ years | Excellent with TKI; blast crisis = poor |
Critical NBE distinguisher: Auer rods are pathognomonic for AML (especially AML-M3/APL). If the question mentions Auer rods, the answer is AML, and if it mentions disseminated intravascular coagulation in a leukemia patient, the answer is AML-M3 (APL) treated with ATRA.
Lymphoma: Hodgkin vs non-Hodgkin
Hodgkin lymphoma (HL) — Reed-Sternberg cell variants:
| Type | RS cell variant | Frequency | Prognosis |
|---|---|---|---|
| Nodular sclerosis | Lacunar cells | Most common in developed countries | Good |
| Mixed cellularity | Classic RS cells | Common in India; EBV-associated | Intermediate |
| Lymphocyte-rich | Classic RS cells (rare) | Uncommon (~5%) | Best |
| Lymphocyte-depleted | Pleomorphic RS cells | Rarest (<1%); HIV association | Worst |
| Nodular lymphocyte-predominant | Popcorn cells (L&H cells) | CD20+, CD15-, CD30- | Excellent; behaves like B-cell lymphoma |
Reed-Sternberg cell: Large binucleate or multinucleate cell with prominent eosinophilic "owl eye" nucleoli. CD15+ and CD30+ (with rare exception of nodular lymphocyte-predominant HL). Origin: germinal center B-cell that has lost normal B-cell markers.
Hodgkin vs Non-Hodgkin lymphoma:
| Feature | Hodgkin lymphoma | Non-Hodgkin lymphoma |
|---|---|---|
| Spread | Contiguous node groups | Non-contiguous; skip areas |
| Extranodal | Rare | Common |
| Bone marrow | Rarely involved | Commonly involved |
| Mediastinal mass | Common (especially nodular sclerosis) | Variable |
| B symptoms | Classic (fever, night sweats, weight loss) | Variable |
| Treatment | ABVD chemotherapy ± radiotherapy | Depends on type (RCHOP for diffuse large B-cell) |
| Prognosis | Generally excellent (80%+ cure overall) | Variable by histological subtype |
Immunopathology: hypersensitivity and autoimmune diseases
Immunopathology is the study of diseases caused by disordered immune responses — contributing 3–5 questions per NEET PG, with the four types of hypersensitivity reactions and autoimmune antibody associations as the most reliably tested areas.
Hypersensitivity reactions — Types I to IV
| Type | Mechanism | Mediator | Onset | Prototype diseases |
|---|---|---|---|---|
| Type I (Immediate/Anaphylactic) | IgE bound to mast cells; allergen cross-links IgE → degranulation | Histamine, leukotrienes, prostaglandins | Minutes | Anaphylaxis, atopic asthma, hay fever, urticaria, food allergy |
| Type II (Antibody-mediated/Cytotoxic) | IgG or IgM binds to cell surface antigen; complement activation or ADCC | Complement, NK cells, macrophages | Hours | Goodpasture syndrome (anti-GBM), hemolytic transfusion reaction, Graves disease (TSI), myasthenia gravis (anti-AChR) |
| Type III (Immune complex-mediated) | Antigen-antibody complexes deposit in tissues; complement activation | C3a, C5a; neutrophil enzymes | 4–12 hours | SLE, post-streptococcal GN, serum sickness, Arthus reaction, farmer's lung |
| Type IV (Delayed/Cell-mediated) | CD4+ T-helper cells (TH1); macrophage activation; CD8+ cytotoxic T cells | IL-2, IFN-gamma, TNF-alpha | 48–72 hours | Contact dermatitis (poison ivy, nickel), PPD tuberculin test, graft rejection, multiple sclerosis |
NBE examination pattern: The question presents a clinical scenario with a time course and asks for the hypersensitivity type. The time course is the key clue: immediate (minutes) = Type I; hours with tissue damage = Type II (or Type III if complement low); 48–72 hours = Type IV. An indurated PPD test read at 48–72 hours is always Type IV.
Autoimmune disease antibody associations
| Disease | Key antibodies | Clinical significance |
|---|---|---|
| SLE | Anti-dsDNA (highly specific, correlates with activity), Anti-Smith (highly specific), ANA (sensitive, not specific), Anti-histone (drug-induced lupus) | Anti-dsDNA titer tracks disease activity |
| Rheumatoid arthritis | Rheumatoid factor (IgM anti-IgG), Anti-CCP (most specific, appears early) | Anti-CCP predicts erosive disease |
| Sjogren syndrome | Anti-Ro/SSA, Anti-La/SSB | Anti-Ro causes neonatal lupus and heart block in neonate |
| Scleroderma (diffuse) | Anti-Scl-70 (anti-topoisomerase I) | Associated with pulmonary fibrosis |
| Scleroderma (limited/CREST) | Anti-centromere | CREST: Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasia |
| Primary biliary cholangitis | Anti-mitochondrial (AMA) M2 | Highly specific; granulomatous destruction of bile ducts |
| Autoimmune hepatitis | Anti-smooth muscle (ASMA), ANA (Type 1); Anti-LKM1 (Type 2) | AST/ALT-driven hepatitis; hypergammaglobulinemia |
| Goodpasture syndrome | Anti-GBM (anti-type IV collagen, alpha-3 chain) | Pulmonary hemorrhage + rapidly progressive GN |
| Wegener/GPA | c-ANCA (anti-PR3) | Upper + lower respiratory tract + renal triad |
| Microscopic polyangiitis | p-ANCA (anti-MPO) | Renal-predominant; pauci-immune GN |
Transplant rejection types
| Type | Timing | Mechanism | Histology | Treatment |
|---|---|---|---|---|
| Hyperacute | Minutes to hours after transplant | Preformed antibodies (Type II hypersensitivity) | Thrombosis, ischemic necrosis | Irreversible; must remove graft |
| Acute cellular | Days to months | CD8+ T-cell mediated; CD4+ T-cell mediated | Lymphocytic infiltration of parenchyma | Reversible with immunosuppression (pulse steroids) |
| Acute humoral (vascular) | Days to months | Donor-specific antibodies (DSA); C4d deposition | Vasculitis, C4d+ on peritubular capillaries | Plasmapheresis + IVIG |
| Chronic | Months to years | Both T-cell and antibody-mediated | Vascular intimal thickening, fibrosis, parenchymal loss | Largely irreversible; slow progression to graft failure |
Genetic disorders: chromosomal and single-gene diseases
Genetic disorders are diseases caused by abnormalities in the genome — contributing 2–4 questions per NEET PG, with chromosomal disorder karyotypes and single-gene disorder inheritance patterns as the primary test targets.
Chromosomal disorders — karyotypes and clinical features
| Disorder | Karyotype | Incidence | Cardinal features | NBE-tested fact |
|---|---|---|---|---|
| Down syndrome (Trisomy 21) | 47, XX or XY, +21 (95%); Robertsonian translocation (4%); mosaic (1%) | 1:700 live births | Flat face, epicanthal folds, upward slanting palpebral fissures, Brushfield spots, simian crease, duodenal atresia, AV septal defect, Alzheimer disease early | Maternal age most important risk factor; risk increases after 35 |
| Edwards syndrome (Trisomy 18) | 47, XX or XY, +18 | 1:5,000 | IUGR, rocker-bottom feet, overlapping fingers, micrognathia, VSD, omphalocele | Most die within 1 year; 2nd most common autosomal trisomy |
| Patau syndrome (Trisomy 13) | 47, XX or XY, +13 | 1:10,000 | Holoprosencephaly, cyclopia, polydactyly, cleft lip/palate, microphthalmia | Most severe autosomal trisomy; 3rd most common |
| Turner syndrome | 45, X (50%); mosaic 45,X/46,XX; isochromosome Xq | 1:2,500 female births | Short stature, webbed neck, shield chest, primary amenorrhea, streak gonads, coarctation of aorta, bicuspid aortic valve | Most common cause of primary amenorrhea; intelligence normal |
| Klinefelter syndrome | 47, XXY | 1:1,000 male births | Tall stature, gynecomastia, small firm testes, hypogonadism, infertility, behavioral issues | Most common cause of hypogonadism and infertility in males; FSH and LH elevated, testosterone low |
| Cri-du-chat | 46, del(5p) | Rare | High-pitched cat-like cry, microcephaly, intellectual disability, round face | Deletion of short arm of chromosome 5 |
Single-gene disorders — inheritance and key features
| Disease | Inheritance | Mutation | Key clinical feature | NBE-tested fact |
|---|---|---|---|---|
| Cystic fibrosis | Autosomal recessive | CFTR gene, delta-F508 most common | Recurrent pulmonary infections, exocrine pancreatic insufficiency, elevated sweat chloride (>60 mEq/L), male infertility (absent vas deferens) | Most common lethal autosomal recessive disease in Caucasians; Pseudomonas aeruginosa is the main pathogen in adults |
| Sickle cell disease | Autosomal recessive | HBB gene, E6V substitution (glutamate → valine) | Vaso-occlusive crises, hemolytic anemia, dactylitis, autosplenectomy, HbS on electrophoresis | Sickling occurs with deoxygenation, acidosis, dehydration; HbF inhibits sickling |
| Marfan syndrome | Autosomal dominant | FBN1 (fibrillin-1) gene | Tall stature, arachnodactyly, lens dislocation (upward), aortic root dilatation/dissection, MVP | Lens dislocation upward in Marfan (downward in homocystinuria — key differentiator) |
| Huntington disease | Autosomal dominant | HTT gene, CAG trinucleotide repeat expansion (>36 repeats) | Chorea, psychiatric symptoms, dementia; onset 30–50 years | Anticipation (earlier onset in successive generations); 100% penetrance |
| Duchenne muscular dystrophy | X-linked recessive | DMD gene (dystrophin), frameshift deletion | Progressive proximal muscle weakness from age 3–5; Gower sign; pseudohypertrophy of calves; dilated cardiomyopathy | Elevated CPK (earliest and most sensitive); death by early 20s; Becker MD = in-frame deletion (milder) |
| Fragile X syndrome | X-linked (dominant with reduced penetrance) | FMR1 gene, CGG repeat expansion (>200 repeats) | Most common inherited intellectual disability in males; macro-orchidism, long face, large ears, autism features | Pre-mutation (55–200 repeats) = premutation carrier; premutation women risk premature ovarian failure |
Imprinting disorders — NBE-tested pair:
| Disorder | Chromosome | Imprinting defect | Features |
|---|---|---|---|
| Prader-Willi syndrome | 15q11-13, paternal deletion or maternal UPD | Loss of paternal 15q11-13 | Obesity, hyperphagia, intellectual disability, hypogonadism, hypotonia at birth |
| Angelman syndrome | 15q11-13, maternal deletion or paternal UPD | Loss of maternal 15q11-13 (UBE3A) | "Happy puppet" — severe intellectual disability, absent speech, ataxic gait, seizures, inappropriate laughter |
Systemic pathology highlights: organ-wise high-yield
Systemic pathology is the application of general pathological principles to specific organ systems — and NBE tests it through clinicopathological correlations where the histological finding leads to the diagnosis.
Cardiovascular pathology
Myocardial infarction — temporal histological changes:
| Time | Gross | Microscopy |
|---|---|---|
| 0–4 hours | No change | No change (may see wavy fibers on electron microscopy) |
| 4–12 hours | Pallor begins | Coagulation necrosis begins; contraction bands |
| 12–24 hours | Pallor established | Pyknosis, beginning neutrophil infiltration |
| 1–3 days | Hyperemia at borders | Neutrophil infiltration peak |
| 3–7 days | Yellow-brown central softening | Macrophage infiltration; beginning phagocytosis |
| 1–3 weeks | Yellow-white center, red vascular border | Granulation tissue, neovascularization |
| Months | White scar | Dense fibrous scar (collagen I) |
Complications by timing: Day 1–3: arrhythmia (most common cause of death). Day 2–4: early fibrinous pericarditis (local inflammation from transmural necrosis). Day 3–7: rupture (free wall, septum, papillary muscle). 2–10 weeks post-MI: Dressler syndrome (autoimmune pericarditis — distinct from early pericarditis; caused by autoantibodies against myocardial antigens). Weeks to months: ventricular aneurysm.
Pulmonary pathology
Lung cancer types — histological differentiation:
| Type | Location | Histology | Association | Paraneoplastic |
|---|---|---|---|---|
| Squamous cell carcinoma | Central/hilar | Keratin pearls, intercellular bridges | Smoking; Pancoast tumor | Hypercalcemia (PTHrP) |
| Adenocarcinoma | Peripheral subpleural | Glands, mucin production; Clara cells | Nonsmokers, women; EGFR mutations | Hypertrophic osteoarthropathy |
| Small cell (oat cell) | Central | Small cells with scant cytoplasm, nuclear molding; neuroendocrine markers | Smoking; very aggressive; early metastasis | SIADH, ectopic ACTH, Lambert-Eaton |
| Large cell carcinoma | Peripheral | No squamous, glandular, or small cell features; diagnosis of exclusion | Smoking | Variable |
| Bronchioloalveolar (now lepidic adenocarcinoma) | Peripheral | Tumor cells grow along alveolar walls (lepidic growth); no stromal invasion | Non-smokers; EGFR, ALK mutations | None |
Hepatic pathology
Liver cirrhosis causes and histological patterns: Macronodular cirrhosis (nodules >3mm): viral hepatitis B and C, Wilson disease, hemochromatosis. Micronodular cirrhosis (nodules <3mm): alcoholic liver disease, biliary cirrhosis, hemochromatosis (early). Mixed: any cause at late stage.
Wilson disease vs hemochromatosis — NBE differentiator:
| Feature | Wilson disease | Hemochromatosis |
|---|---|---|
| Metal | Copper (ATP7B mutation) | Iron (HFE gene, C282Y mutation) |
| Inheritance | Autosomal recessive | Autosomal recessive |
| Age of presentation | Young adults (5–35 years) | Middle-aged adults |
| Liver | Cirrhosis, acute liver failure | Cirrhosis |
| Other organs | Kayser-Fleischer rings (copper in Descemet membrane); neuropsychiatric; hemolysis | Diabetes mellitus ("bronze diabetes"), cardiomyopathy, hypogonadism, arthropathy |
| Stain | Rhodanine (copper); Orcein | Prussian blue (iron); Perls stain |
| Treatment | D-penicillamine or trientine; zinc | Phlebotomy; desferrioxamine if phlebotomy contraindicated |
CNS pathology — tumor classification
| Tumor | Origin | WHO Grade | Key feature | Age |
|---|---|---|---|---|
| Glioblastoma multiforme (GBM) | Astrocyte (Grade IV astrocytoma) | IV | Pseudopalisading necrosis, vascular proliferation; butterfly pattern crossing corpus callosum | Adults; median survival 15 months |
| Meningioma | Arachnoid cap cells | I (usually) | Psammoma bodies (whorls with calcification); parasagittal, convexity | Adults; women > men; benign, slow-growing |
| Medulloblastoma | Cerebellar vermis, granule cell precursors | IV (high-grade) | Homer-Wright pseudorosettes; formerly PNET (reclassified as 'Embryonal tumor' per WHO CNS 5th Edition 2021); drop metastases via CSF | Children; most common malignant brain tumor in children |
| Schwannoma | Schwann cells of cranial nerve VIII | I | Antoni A (compact spindle cells, Verocay bodies) + Antoni B (loose myxoid areas); S-100+ | Adults; acoustic neuroma at cerebellopontine angle |
| Craniopharyngioma | Rathke pouch remnant | I | Calcification; "machine oil" fluid; cholesterol crystals | Children and young adults; suprasellar mass; bitemporal hemianopia |
| Oligodendroglioma | Oligodendrocyte | II–III | Fried-egg appearance (perinuclear halo); chicken-wire capillaries; calcification | Adults; frontal lobe; 1p/19q co-deletion = good prognosis |
Laboratory investigations and staining patterns: special stains and IHC markers
Laboratory pathology is the application of histochemical and immunohistochemical techniques to identify specific tissue components — and NBE consistently tests 2–3 questions on special stain-target associations and IHC marker-tumor associations.
Special stains — comprehensive table
| Stain | Target/Substance | Colour | Diagnostic use |
|---|---|---|---|
| Hematoxylin and eosin (H&E) | Nuclei (blue), cytoplasm/collagen (pink) | Blue + pink | Routine tissue examination — used for all primary diagnosis |
| Periodic acid-Schiff (PAS) | Glycogen, mucopolysaccharides, glycoproteins, fungal cell walls | Magenta/pink | Glycogen storage diseases, ALL (B-cell), Whipple disease (PAS+++ macrophages), fungal infections |
| Ziehl-Neelsen (ZN / AFB stain) | Mycobacteria (acid-fast bacilli), Nocardia | Red bacilli on blue background | Tuberculosis, leprosy, Nocardiosis |
| Gram stain | Bacterial cell walls | Gram+: purple; Gram-: red | Bacterial identification in tissue |
| Gomori methenamine silver (GMS) | Fungal cell walls, Pneumocystis jirovecii | Black fungi on green background | PCP (Pneumocystis pneumonia), Aspergillus, Cryptococcus, Candida |
| Alcian blue | Acid mucopolysaccharides (mucin) | Blue | Mesothelioma (Alcian blue+, hyaluronidase-sensitive), adenocarcinoma mucin (hyaluronidase-resistant — key diagnostic discriminator from mesothelioma) |
| Mucicarmine | Mucin, Cryptococcus capsule | Red/pink | Cryptococcus (capsule stains red), mucin-secreting adenocarcinomas |
| Congo red | Amyloid | Orange-red; apple-green birefringence under polarized light | Amyloidosis (all types); pathognomonic with polarized light |
| Prussian blue (Perls) | Hemosiderin (iron) | Blue | Hemochromatosis, hemosiderosis, sideroblastic anemia (ring sideroblasts) |
| Rhodanine / Orcein | Copper, elastic tissue | Red/brown | Wilson disease (copper), cirrhosis (elastic fibres) |
| Von Kossa | Calcium (phosphate) | Black | Calcification in tissues |
| Sudan black B / Oil Red O | Lipids, triglycerides | Black / Red | AML (Sudan black B+), fatty liver (Oil Red O); must use frozen sections |
| Masson trichrome | Collagen (blue/green), muscle (red), nuclei (black) | Tricolor | Quantify fibrosis; distinguish fibrosis from muscle |
| Silver (Bielschowsky, Bodian) | Axons, neurofibrils, reticulin | Black | CNS axonal pathology, reticulin fibre pattern in liver tumors |
| Warthin-Starry | Spirochetes (Treponema, Bartonella), Helicobacter pylori | Black on yellow | Syphilis, cat scratch disease, H. pylori gastritis |
| Toluidine blue | Mast cell granules, metachromatic material | Purple | Mast cell tumors, mastocytosis |
IHC markers for tumor identification
| IHC Marker | Positive tumors | Key association |
|---|---|---|
| Cytokeratin (AE1/AE3, CAM5.2) | All carcinomas | Epithelial lineage marker; distinguishes carcinoma from lymphoma, sarcoma |
| Vimentin | Sarcomas, melanoma, some carcinomas (RCC) | Mesenchymal lineage |
| S-100 | Melanoma, schwannoma, Langerhans cell histiocytosis, chondrosarcoma, salivary gland tumors | Neural crest origin |
| HMB-45 / Melan-A | Melanoma (specific) | More specific than S-100 for melanoma |
| CD20 | B-cell lymphomas | Target of rituximab |
| CD3 | T-cell lymphomas | Pan-T-cell marker |
| CD30 | Reed-Sternberg cells (Hodgkin), anaplastic large cell lymphoma | Ki-1 antigen; target of brentuximab |
| CD15 | Reed-Sternberg cells (Hodgkin) | Distinguishes classic HL from nodular LP HL (CD15-, CD20+) |
| CD117 (c-KIT) | GIST (gastrointestinal stromal tumor), AML-M2 | Target of imatinib in GIST |
| Desmin | Rhabdomyosarcoma, leiomyosarcoma | Muscle differentiation |
| PSA | Prostate carcinoma | Tissue PSA confirms prostate origin in metastatic disease |
| Thyroglobulin | Follicular and papillary thyroid carcinoma | Confirms thyroid origin |
| Calcitonin | Medullary thyroid carcinoma | C-cell origin; pathognomonic |
| Chromogranin A / Synaptophysin | All neuroendocrine tumors (carcinoid, SCLC, pheochromocytoma, Merkel cell) | Neuroendocrine differentiation |
| Alpha-fetoprotein (AFP, tissue) | Hepatocellular carcinoma, yolk sac tumor | Hepatic and germ cell origin |
| CD10 (CALLA) | B-ALL, follicular lymphoma, RCC (clear cell), endometrial stromal sarcoma | B-cell precursor marker in ALL; used in renal tumor panel |
| ER / PR | Breast carcinoma | Predict response to hormonal therapy (tamoxifen, aromatase inhibitors) |
| HER2/neu (c-erbB2) | Breast carcinoma, gastric carcinoma | Overexpression/amplification predicts response to trastuzumab |
| TTF-1 (thyroid transcription factor-1) | Lung adenocarcinoma, SCLC, thyroid tumors | Distinguishes lung primary from other adenocarcinomas |
Practice 10 pathology MCQs on staining patterns free →
Study strategy: converting pathology knowledge into exam marks
Study strategy for pathology is the systematic approach to converting a mechanistically rich subject into reliable MCQ performance — and it differs from clinical subjects because Pathology is tested through histological descriptions, morphological associations, and classification tables rather than clinical decision-making.
The 3-phase approach for pathology
Phase 1 — Conceptual foundation (2 weeks). Study one chapter per day using Robbins Basic Pathology or an equivalent PG prep guide. For each topic, build a one-page table: the general pathway (mechanism) + the classic histological finding + the NBE-tested association. Do not memorize isolated facts — understand why coagulative necrosis preserves ghost outlines (early protein denaturation inactivates enzymes) and every necrosis question becomes solvable by logic.
Phase 2 — Table-based high-yield revision (1 week). Extract and drill only the tables from this guide: the five necrosis types, the four hypersensitivity mechanisms, the tumor markers table, the leukemia comparison, and the special stains table. Solve 30 pathology MCQs daily — 15 from a question bank and 15 from previous NEET PG papers. Categorize errors: morphology error, mechanism error, or classification error. Each error type needs a different revision strategy.
Phase 3 — Integration and rapid revision (3–4 days before exam). On each day, revise one table under timed conditions (5 minutes per table without looking at notes). On the final day, review: Auer rods = AML, Reed-Sternberg cell = Hodgkin lymphoma, Congo red + apple-green birefringence = amyloid, Philadelphia chromosome = CML, p53 mutation = most common genetic alteration in human cancers. These are the guaranteed 1-mark items.
For integration with clinical subjects, read our Surgery high-yield guide — surgical pathology (TNM staging, histological criteria for malignancy, wound healing) directly overlaps with pathology content tested in both papers. Apply the spaced repetition method to build a pathology flashcard deck — tables for necrosis types, tumor markers, and staining patterns are ideal spaced repetition material because they contain discrete, high-value facts.
Sources and references
- Robbins and Cotran Pathologic Basis of Disease, 10th Edition (Kumar, Abbas, Aster, 2021) — the canonical reference for NEET PG Pathology; all mechanisms and morphological descriptions in this guide are based on Robbins.
- Robbins Basic Pathology, 10th Edition (Kumar, Abbas, Aster, 2018) — concise version recommended for primary PG exam preparation.
- Harsh Mohan's Textbook of Pathology, 8th Edition (2019) — widely used Indian pathology reference aligned with NMC curriculum; strong on Indian-context epidemiology.
- WHO Classification of Tumours (5th Edition Blue Books, 2022) — organ-specific tumor classifications, grading criteria, and IHC marker standards.
- WHO Classification of Haematolymphoid Tumours, 5th Edition (2022) — current classification of leukemias and lymphomas including updated genetic criteria.
- Harrison's Principles of Internal Medicine, 21st Edition (Loscalzo et al., 2022) — source for paraneoplastic syndromes and systemic pathology clinicopathological correlations.
Frequently asked questions
How many pathology questions appear in NEET PG?
Pathology contributes 18–24 questions to NEET PG, making it one of the highest-weighted preclinical subjects. Neoplasia, hematopathology, and cell injury are the three most reliably tested areas, collectively accounting for 10–14 questions most years. Focused preparation on these areas yields the highest return.
Which pathology topics are tested most frequently in NEET PG?
Tumor markers, types of necrosis, leukemia differentiation (ALL/AML/CLL/CML), hypersensitivity reactions (Types I–IV), anemia classification by MCV, special staining patterns, and chromosomal disorder karyotypes dominate consistently across recent papers. Granulomatous inflammation causes and paraneoplastic syndromes also appear every year.
Should I read Robbins cover-to-cover for NEET PG pathology?
No. Robbins is the gold standard for understanding mechanisms, but reading it cover-to-cover is not the most efficient exam strategy. Use the concise version (Robbins Basic Pathology or a standard PG prep guide) to build concept maps, then drill MCQs. Reserve detailed Robbins chapters for neoplasia and hematopathology where mechanism depth directly translates to marks.
How do I remember all the tumor markers for NEET PG?
Organize tumor markers as tables by organ system rather than memorizing them as isolated facts. Associate each marker with a clinical scenario: AFP + hepatocellular carcinoma in a patient with cirrhosis; PSA + prostate nodule in an older man; CA-125 + pelvic mass in a woman. The vignette context triggers marker recall faster than rote memorization.
What is the best way to learn hypersensitivity reactions for NEET PG?
Learn the four types with one anchor disease each — Type I: anaphylaxis; Type II: Goodpasture syndrome; Type III: post-streptococcal glomerulonephritis; Type IV: contact dermatitis. Then expand to secondary examples for each type. The mechanism (IgE, antibody, immune complex, T-cell) is always the tested differentiator, not the disease name alone.
How do I differentiate ALL, AML, CLL, and CML for NEET PG?
Build a comparison table with five rows: age, cell type, cytochemistry marker, cytogenetic marker, and treatment. ALL: children, TdT+, Philadelphia chromosome in 20–25% of adult cases; AML: adults, MPO+, Auer rods; CLL: elderly, CD5+ CD23+ smudge cells, indolent; CML: middle-aged, BCR-ABL Philadelphia chromosome, imatinib. Practice the table until each column comes automatically.
How should I approach genetic disorders in pathology preparation?
Focus on karyotypes and cardinal clinical features for chromosomal disorders (Down 47+21, Turner 45X, Klinefelter 47XXY, Edwards 47+18, Patau 47+13). For single-gene disorders, learn the inheritance pattern and one pathognomonic feature per disease. Chromosomal banding patterns and FISH probes are high-yield for 1–2 image-based questions per paper.
What is the single most effective last-minute pathology revision strategy?
In the final two weeks, revise four tables daily: tumor markers by organ, necrosis types with examples, hypersensitivity mechanisms with diseases, and special stains with targets. Solve 30 pathology MCQs under timed conditions daily. On the final day, review only Auer rods, Philadelphia chromosome, Reed-Sternberg cells, and the five types of necrosis — these appear in nearly every paper.
Start your pathology prep today. Open the Pathology subject page and solve your first 15 MCQs — the morphological patterns you drill now are the patterns you will recognize on exam day.
Start practicing pathology MCQs free →
See our pricing plans for unlimited practice across all 19 subjects.
Written by: NEETPGAI Editorial Team Reviewed by: Dr. SME Agent, NEETPGAI Medical Advisory Board Last reviewed: April 2026
This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.
Ready to put this into practice?
Start practicing NEET PG MCQs with AI-powered explanations.
Start Free PracticeRelated Study Guides
NEET PG Medicine High-Yield Topics — Complete Guide 2026
Master every high-yield medicine topic for NEET PG 2026: cardiology, endocrinology, nephrology, hematology, neurology, gastroenterology, infectious disease, and rheumatology with real exam patterns and study strategies.
Complete Guide to NEET PG Surgery High-Yield Topics
Master every high-yield surgery topic for NEET PG: surgical anatomy, GI surgery, trauma, hernias, breast, thyroid, urology, and vascular surgery with real exam facts and study strategies.
How to Use Spaced Repetition for NEET PG — The Science-Backed Study Method
Master spaced repetition for NEET PG: understand the Ebbinghaus forgetting curve, SM-2 algorithm, optimal review intervals, and how to build subject-wise SR decks that triple long-term retention.